A phase II, randomised, double-blind, international, multicentre, placebo-controlled, dose-ranging, parallel-group study to evaluate the efficacy and safety of orally administered Rob 803 [rabeximod] when added to stable methotrexate.

Trial Profile

A phase II, randomised, double-blind, international, multicentre, placebo-controlled, dose-ranging, parallel-group study to evaluate the efficacy and safety of orally administered Rob 803 [rabeximod] when added to stable methotrexate.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Rabeximod (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ROBUST
  • Sponsors OxyPharma
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 30 Nov 2009 Preliminary results were reported in an OxyPharma media release.
    • 19 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top